Reports of Arc-10's failure are greatly exaggerated, the company argues.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.